Swiss life science company Arcoris Bio has raised €6.7 million (CHF 6.3 million) in an oversubscribed Seed round to accelerate the development and commercialization of its MUSE biomarker detection platform.
The funding was co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and both new and existing private investors.
Founded in 2022 by Simon Restrepo, Scott E. Fraser, and H. Kaspar Binz, Arcoris Bio develops advanced tools for biomarker detection and digital pathology, aiming to make high-sensitivity diagnostics more accessible and data-driven. Its flagship MUSE platform enables universal, programmable signal amplification, allowing researchers and clinicians to perform highly sensitive multiplex assays for next-generation diagnostics and drug discovery.
“Attracting two lead investors with deep industry expertise is a strong validation of our technical and business strategy,” said Simon Restrepo, co-founder and CSO of Arcoris Bio. “This support empowers us to continue transforming biomarker detection and digital pathology.”
Powering the next wave of digital diagnostics
The MUSE platform addresses a critical gap in biomarker detection by offering a universal amplification technology that can enhance the performance of existing imaging and diagnostic systems — a concept Restrepo describes as acting like a “molecular GPU” for biomarker analysis.
“MUSE’s universal applicability is particularly exciting — it amplifies the capabilities of existing biomarker platforms and opens new paths for innovation,” said Benedikt Klaes, Senior Investment Manager at ZEISS Ventures.
“We have been impressed by the Arcoris Bio team’s vision and early traction with industry partners,” added Andreas Jenne, Investment Director at Ventura Ace. “We believe MUSE represents a truly enabling technology for digital pathology.”
Advertisement
Scaling for commercialization
The new funding will allow the company to industrialize its MUSE platform, expand strategic partnerships, and accelerate new product launches as it positions itself among Europe’s most advanced diagnostics technology players.
“Securing this financing marks a major milestone for Arcoris Bio,” said Matyas Vegh, CEO. “In a challenging market, we’re grateful for the trust our investors have placed in our vision. Their support will help us bring our innovations to market faster and scale to meet growing industry demand.”
Arcoris Bio’s growth reflects a broader European surge in deeptech and life science investment, with diagnostic and biomarker startups increasingly attracting capital to build the infrastructure for precision medicine and data-driven healthcare.
About Arcoris Bio
Arcoris Bio AG, based in Schlieren, Switzerland, develops highly sensitive multiplex imaging kits and detection solutions for immunofluorescence, RNA FISH, and FACS applications. Through its flagship MUSE platform, Arcoris Bio enables researchers and clinicians to achieve more precise, data-rich insights for diagnostics, drug discovery, and translational research — empowering the next generation of personalized medicine
